James Graham Brown Foundation

Recent papers from James Graham Brown Foundation

1. C3- and C5-deficient murine cells exhibit severe mitochondrial defects, indicating a pivotal, novel role of innate immunity in regulating hematopoiesis at the electron transfer chain levelLeukemia · 2026
2. 3 Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)The Oncologist · 2026
3. The Relationship Between Heart Rate Variability and Interoception in Anorexia Nervosa Spectrum DisordersInternational Journal of Eating Disorders · 2026
4. Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancerFrontiers in Oncology · 2026
5. Evaluation of accuracy and potential biases of imputation methods on biomedical datasets subject to different mechanisms and patterns of missingnessComputer Methods and Programs in Biomedicine Update · 2026
6. Adipocyte-derived LTB4 programs human NKG2A ⁺ γδ T cells as cytotoxic sentinels at the adipose-tumor interface in breast cancerJournal for ImmunoTherapy of Cancer · 2026
7. Association of chemotherapy with survival in node-positive penile squamous cell carcinoma stratified by nodal burden: A National Cancer Database analysis.Journal of Clinical Oncology · 2026
8. NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.Journal of Clinical Oncology · 2026
9. Outpatient administration of cycle 1 of bispecific antibody therapy in hematologic malignancies: A real-world experience.Journal of Clinical Oncology · 2026
10. BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.Journal of Clinical Oncology · 2026
11. A velocity-informed framework for resolving functional stratification in rare human stem cellsLeukemia · 2026
12. “The Only Way to Survive is by Taking Care of One Another”: Grace Lee Boggs on the Feminist Revolution From BelowGender & Society · 2026
13. The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer – results from the NRG/RTOG 1016 trialCancer Research Communications · 2026
14. Abstract LB-A010: Translational data validate OBX-115 mechanism of action: Impact of dosing on clinical outcome in advanced (adv) melanomaCancer Immunology Research · 2026
15. Evaluation of quality of life endpoint planning and reporting in phase III genitourinary oncology randomized controlled trials.Journal of Clinical Oncology · 2026
16. Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.Journal of Clinical Oncology · 2026
17. PS5-09-30: A phase 1/2 trial evaluating the safety, tolerability, and efficacy of the KAT6 inhibitor, PF-07248144, in combination with vepdegestrant in patients with ER+/HER2− locally advanced or metastatic breast cancerClinical Cancer Research · 2026
18. Perioperative Outcomes of Rural-Dwelling Patients Undergoing Lung and Colon Cancer Operation in Rural FacilityJournal of the American College of Surgeons · 2026
19. A c-Cbl/Cbl-b antagonist inhibits EGFR ubiquitylation and sustains EGFR phosphorylation to enhance corneal re-epithelializationProceedings of the National Academy of Sciences · 2026
20. Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.Journal of Clinical Oncology · 2026